Company: NCEL
Filing Date: 2025-09-04
Form Type: 425
Source: 0001213900-25-084283
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-09-04
Form: 425
Chunk 2
---
 International Diabetes Federation estimated in 2024 that approximately 706,000 adults in Hong Kong are living
with diabetes, representing an 8.2% prevalence among the adult population, a figure supported by the Hong Kong Department
of Health’s 2020–2022 Population Health Survey, which found an 8.5% prevalence of diabetes or raised blood glucose among
individuals aged 15–84. Lifetime healthcare expenditures for individuals diagnosed with diabetes (men and women) are
substantial, averaging $125,000 per patient in 2017. Applied to Hong Kong’s adult diabetes population, this represents
a potential economic impact of approximately $90 billion.

| 1 | https://idf.org/our-network/regions-and-members/western-pacific/members/hong-kong/ |

| 2 | https://www.chp.gov.hk/en/features/103652.html |

| 3 | https://hub.hku.hk/handle/10722/280089#:~:text=Eesults:%20The%20lifetime%20health%20care,high%20lifetime%20health%20care%20costs. |

About IsletRx

Kadimastem’s IsletRx platform aims to provide
a scalable, stem cell–derived source of insulin-producing islet-like cells capable of secreting insulin and glucagon in response
to glucose levels. The program is designed to address key challenges in diabetes care by supplying functional endocrine cells for transplant.

About NLS Pharmaceutics

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a Swiss-based
biopharmaceutical company focused on the development of innovative therapies for central nervous system disorders and related indications.
For more information, visit www.nlspharma.com.

About Kadimastem

Kadimastem Ltd. (TASE: KDST) is a clinical-stage
cell therapy company developing allogeneic, “off-the-shelf” cell products for neurodegenerative diseases and diabetes. For
more information, visit www.kadimastem.com.

Forward-Looking Statements

This press release contains expressed or
implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS and Kadimastem are using
forward-looking statements when they discuss that IsletRx as potentially a cure for insulin-dependent diabetes, that expanding IP
protection in Hon Kong supports supports the long-term strategy for IsletRx and